Surgery is the preferred treatment; however, there are no clear guideline for its treatment.[24] In TFEB-associated renal cell carcinoma, overexpression of mTORC1 induced by TFEB is a key step in kidney, bladder formation and tumorigenesis.[25] Zhang et al[26] found that TFEB binds to PD-L1 promoter in RCC and inhibits mTOR, leading to nuclear translocation of TFEB and enhanced expression of PD-L1. The gene discussed is MTOR; the disease is renal cell adenocarcinoma.